Recommendations for the treatment of invasive fungal infections in hematological malignancies: A critical review of evidence and Turkish Expert Opinion (TEO-1)

Simple item page
dc.contributor.authorAkan, Hamdi
dc.contributor.authorÖngören, Şeniz
dc.contributor.authorSaltoğlu, Neşe
dc.contributor.authorÇağatay, Arif Atahan
dc.contributor.authorArat, Mutlu Ersöz
dc.contributor.authorKalayoğlu, Sevgi B.
dc.contributor.authorDemir, Ahmet Muzaffer
dc.contributor.buuauthorAkalın, Halis
dc.contributor.buuauthorAli, Rıdvan
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Hematoloji Anabilim Dalı.tr_TR
dc.contributor.researcheridAAU-8952-2020tr_TR
dc.contributor.scopusid57207553671tr_TR
dc.contributor.scopusid7201813027tr_TR
dc.date.accessioned2024-02-08T06:29:52Z
dc.date.available2024-02-08T06:29:52Z
dc.date.issued2014-05-12
dc.description.abstractThe introduction of novel antifungal agents for the treatment of invasive fungal disease in hematological malignancies and also changing treatment strategies have had a great impact in managing affected patients. The medical literature includes some important clinical studies that are being used as evidence for guidelines. The problem with these studies and the guidelines is that they are not very easy to interpret, they include controversial issues, and they are not easy to apply to every patient or country. This paper was designed to critically show the main problems associated with these approaches and provide important information that will help Turkish doctors to adopt them in daily clinical practice.tr_TR
dc.identifier.citationAkalın, H. vd. (2014). "Recommendations for the treatment of invasive fungal infections in hematological malignancies: A critical review of evidence and Turkish Expert Opinion (TEO-1)". Turkish Journal of Hematology, 31(2), 111-120.tr_TR
dc.identifier.endpage120tr_TR
dc.identifier.issn1300-7777
dc.identifier.issn1308-5263
dc.identifier.issue2tr_TR
dc.identifier.pubmed25035667tr_TR
dc.identifier.scopus2-s2.0-84905912115tr_TR
dc.identifier.startpage111tr_TR
dc.identifier.urihttps://doi.org/10.4274/tjh.2014.0103
dc.identifier.urihttps://jag.journalagent.com/tjh/pdfs/TJH_31_2_111_120.pdf
dc.identifier.urihttps://hdl.handle.net/11452/39593
dc.identifier.volume31tr_TR
dc.identifier.wos000338094600001
dc.indexed.pubmedPubMedtr_TR
dc.indexed.wosSCIE
dc.language.isoentr_TR
dc.publisherGalenos Publ Housetr_TR
dc.relation.collaborationYurt içitr_TR
dc.relation.collaborationSanayitr_TR
dc.relation.journalTurkish Journal of Hematologytr_TR
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/openAccesstr_TR
dc.subjectAntifungal treatmenttr_TR
dc.subjectInvasive fungal infectiontr_TR
dc.subjectEvidencetr_TR
dc.subjectHematological malignanciestr_TR
dc.subjectLiposomal amphotericin-btr_TR
dc.subjectEfficacytr_TR
dc.subjectPreemptive antifungal therapytr_TR
dc.subjectVoriconazoletr_TR
dc.subjectNeutropenic patientstr_TR
dc.subjectAmbisometr_TR
dc.subjectEmpirical-treatmenttr_TR
dc.subjectFebriletr_TR
dc.subjectPersistent fevertr_TR
dc.subjectHigh-risktr_TR
dc.subjectHematologytr_TR
dc.subject.emtreeAllogeneic stem cell transplantationtr_TR
dc.subject.emtreeAntifungal activitytr_TR
dc.subject.emtreeAntimicrobial therapytr_TR
dc.subject.emtreeAntiviral therapytr_TR
dc.subject.emtreeAspergillosistr_TR
dc.subject.emtreeAutologous stem cell transplantationtr_TR
dc.subject.emtreeCandidemiatr_TR
dc.subject.emtreeCandidiasistr_TR
dc.subject.emtreeDrug efficacytr_TR
dc.subject.emtreeEsophagus candidiasistr_TR
dc.subject.emtreeFeasibility studytr_TR
dc.subject.emtreeFebrile neutropeniatr_TR
dc.subject.emtreeHematologic malignancytr_TR
dc.subject.emtreeHigh risk patienttr_TR
dc.subject.emtreeHodgkin diseasetr_TR
dc.subject.emtreeHumantr_TR
dc.subject.emtreeMulticenter study (topic)tr_TR
dc.subject.emtreeMultiple myelomatr_TR
dc.subject.emtreeMycosistr_TR
dc.subject.emtreeMyelodysplastic syndrometr_TR
dc.subject.emtreeNephrotoxicitytr_TR
dc.subject.emtreeNeutropeniatr_TR
dc.subject.emtreeNonhodgkin lymphomatr_TR
dc.subject.emtreeNonhumantr_TR
dc.subject.emtreePhase 1 clinical trial (topic)tr_TR
dc.subject.emtreePhase 2 clinical trial (topic)tr_TR
dc.subject.emtreePhysiciantr_TR
dc.subject.emtreeRandomized controlled trial (topic)tr_TR
dc.subject.emtreeReviewtr_TR
dc.subject.emtreeSystemic mycosistr_TR
dc.subject.emtreeAmphotericin b.tr_TR
dc.subject.emtreeAmphotericin b deoxycholatetr_TR
dc.subject.emtreeAmphotericin b lipid complextr_TR
dc.subject.emtreeAntifungal agenttr_TR
dc.subject.emtreeCaspofungintr_TR
dc.subject.emtreeEchinocandintr_TR
dc.subject.emtreeGalactomannantr_TR
dc.subject.emtreeTriazoletr_TR
dc.subject.emtreeVoriconazoletr_TR
dc.subject.scopusAntifungal Agents; Posaconazole; Micafungintr_TR
dc.subject.wosHematologytr_TR
dc.titleRecommendations for the treatment of invasive fungal infections in hematological malignancies: A critical review of evidence and Turkish Expert Opinion (TEO-1)tr_TR
dc.typeArticletr_TR
dc.wos.quartileQ4 (Hematology)

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
TJH_31_2_111_120.pdf
Size:
141.74 KB
Format:
Adobe Portable Document Format
Description:
Download

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science